Prostate tumors, resistant to current antiandrogen therapies, represent a serious clinical challenge. A new report identifies androgen-receptor-dependent liquid condensates as being responsible in part for therapeutic resistance, but, encouragingly, also reveals a novel vulnerability amenable to drug targeting.
|Number of pages||2|
|Journal||Nature Chemical Biology|
|Early online date||13 Oct 2022|
|Publication status||Published - Dec 2022|
- cancer therapy
- cell signalling
- small molecules